119 related articles for article (PubMed ID: 24409973)
1. Beneficial effects of black yeast derived 1-3, 1-6 Beta Glucan-Nichi Glucan in a dyslipidemic individual of Indian origin--a case report.
Ganesh JS; Rao YY; Ravikumar R; Jayakrishnan GA; Iwasaki M; Preethy S; Abraham SJ
J Diet Suppl; 2014 Mar; 11(1):1-6. PubMed ID: 24409973
[TBL] [Abstract][Full Text] [Related]
2. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Ferdinand KC; Davidson MH; Kelly MT; Setze CM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
Weinstein DL; Williams LA; Carlson DM; Kelly MT; Burns KM; Setze CM; Lele A; Stolzenbach JC
Clin Ther; 2013 Aug; 35(8):1186-98. PubMed ID: 23891363
[TBL] [Abstract][Full Text] [Related]
4. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
Roth EM; Rosenson RS; Jones PH; Davidson MH; Kelly MT; Setze CM; Lele A; Thakker K
J Clin Lipidol; 2012; 6(6):534-44. PubMed ID: 23312049
[TBL] [Abstract][Full Text] [Related]
5. Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels.
Makariou SE; Liberopoulos EN; Agouridis AP; Challa A; Elisaf M
J Cardiovasc Pharmacol Ther; 2012 Dec; 17(4):382-6. PubMed ID: 22431864
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of rosuvastatin in achieving target HDL, LDL, triglycerides and total cholesterol levels in type 2 diabetes mellitus (T2DM) with newly diagnosed dyslipidaemia: an open label, nonrandomised, non-interventional and observational study in India.
Shah SN; Arneja J
J Assoc Physicians India; 2013 Oct; 61(10):721-6, 732. PubMed ID: 24772729
[TBL] [Abstract][Full Text] [Related]
7. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
[TBL] [Abstract][Full Text] [Related]
8. Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥ 2 mg/L). cmb@bcm.tmc.edu.
Ballantyne CM; Davidson MH; Setze CM; Kelly MT
J Clin Lipidol; 2011; 5(5):401-7. PubMed ID: 21981842
[TBL] [Abstract][Full Text] [Related]
9. Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein.
Burmeister JE; Miltersteiner DR; Campos BM
J Nephrol; 2009; 22(1):83-9. PubMed ID: 19229822
[TBL] [Abstract][Full Text] [Related]
10. The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment.
Coban E; Afacan B
Platelets; 2008 Mar; 19(2):111-4. PubMed ID: 17852772
[TBL] [Abstract][Full Text] [Related]
11. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
Saougos VG; Tambaki AP; Kalogirou M; Kostapanos M; Gazi IF; Wolfert RL; Elisaf M; Tselepis AD
Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2236-43. PubMed ID: 17656665
[TBL] [Abstract][Full Text] [Related]
12. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
[TBL] [Abstract][Full Text] [Related]
13. Oat-derived beta-glucan significantly improves HDLC and diminishes LDLC and non-HDL cholesterol in overweight individuals with mild hypercholesterolemia.
Reyna-Villasmil N; Bermúdez-Pirela V; Mengual-Moreno E; Arias N; Cano-Ponce C; Leal-Gonzalez E; Souki A; Inglett GE; Israili ZH; Hernández-Hernández R; Valasco M; Arraiz N
Am J Ther; 2007; 14(2):203-12. PubMed ID: 17414591
[TBL] [Abstract][Full Text] [Related]
14. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.
Agouridis AP; Tsimihodimos V; Filippatos TD; Dimitriou AA; Tellis CC; Elisaf MS; Mikhailidis DP; Tselepis AD
Expert Opin Pharmacother; 2011 Dec; 12(17):2605-11. PubMed ID: 21714585
[TBL] [Abstract][Full Text] [Related]
15. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ
Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504
[TBL] [Abstract][Full Text] [Related]
16. Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients.
Ogata N; Fujimori S; Oka Y; Kaneko K
Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):321-4. PubMed ID: 20544514
[TBL] [Abstract][Full Text] [Related]
17. A double-blind, double-dummy, randomized, placebo-controlled trial to evaluate the effect of statin therapy on triglyceride levels in Mexican hypertriglyceridemic patients.
Talavera JO; Martinez G; Cervantes JL; Marin JA; Rodriguez-Briones I; Gonzalez JG; Ocampo R; Sanchez-Mijangos H; Bernal-Rosales LP; Polanco A
Curr Med Res Opin; 2013 Apr; 29(4):379-86. PubMed ID: 23323877
[TBL] [Abstract][Full Text] [Related]
18. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
19. Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia.
Lamendola C; Abbasi F; Chu JW; Hutchinson H; Cain V; Leary E; McLaughlin T; Stein E; Reaven G
Am J Cardiol; 2005 Jan; 95(2):189-93. PubMed ID: 15642550
[TBL] [Abstract][Full Text] [Related]
20. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
Durrington PN; Tuomilehto J; Hamann A; Kallend D; Smith K
Diabetes Res Clin Pract; 2004 May; 64(2):137-51. PubMed ID: 15063607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
